Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-02-14
2006-02-14
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
06998395
ABSTRACT:
Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.
REFERENCES:
patent: 5736154 (1998-04-01), Fuisz
patent: 5788980 (1998-08-01), Nabahi
patent: 5827531 (1998-10-01), Morrison et al.
patent: 5830506 (1998-11-01), Taylor
patent: 5874098 (1999-02-01), Stevens et al.
patent: 5977096 (1999-11-01), Droescher et al.
patent: 6071544 (2000-06-01), Sunvold
patent: 6103256 (2000-08-01), Nabahi
patent: 6143716 (2000-11-01), Meers et al.
patent: 6238284 (2001-05-01), Dittgen et al.
patent: 6251418 (2001-06-01), Ahern et al.
patent: 6339069 (2002-01-01), Meers et al.
patent: 6367929 (2002-04-01), Maiden et al.
patent: 6372248 (2002-04-01), Qin et al.
patent: 6372813 (2002-04-01), Johnson et al.
patent: 6555530 (2003-04-01), Wassermann
patent: WO 99/48502 (1999-09-01), None
Dubey et al., “Estradiol Metabolites Inhit Endothelin Synthesis by an Estrogen Receptor-Independent Mechanism.” Hypertension, vol. 37, pp. 640-644, 2001.
Mokdad, A.H., et al.,J. Am. Medical Assoc. 284:1650 (2000).
Grundy, S.M.,Endocrine 13:155 (2000).
Bergman, R.N., et al.,Journal of Investigative Medicine 49:119 (2001).
Colditz, G.A.,Medicine&Science in Sports&Exercise 31:S663 (1999).
Hall, W.D., et al.,American Journal of the Medical Sciences 313:195 (1997).
Hall, J.E., et al.,Annals of the New York Academy of Sciences 892:91 (1999).
Lepor, N.E., et al.,American Journal of Cardiology 86:107 (2000).
Kernan, W.N., et al.,New England J. Med. 343:1826 (2000).
Oparil, S., et al.,Circulation 95:1301 (1997).
Turner, R., et al.,Diabetes 44:1 (1995).
Tofovic, S.P., et al.,Renal Failure 22:387 (2000).
Ball, P., et al.,Endocrinology 113:1781 (1983).
Dubey, R.K., et al.,Hypertension 31:522 (1998).
Dubey, R.K., et al.,Biochem. Biophys. Res. Commun. 278:27 (2000).
Dubey, R.K., et al.,Am. J. Physiol. Renal Physiol. 280:F365 (2001).
Dubey, R.K., et al.,J. Appl. Physiol. 91:1868 (2001).
Dubey, R.K., et al.,Hypertention 37:640 (2001).
Dubey, R.D., et al.,Circ. Res. 84:229 (1999).
Gupta, M., et al.,J. Steriod Biochem. Molec. Biol. 67:413 (1998).
Harris, R.B.,Annu. Rev. Nutr. 20:45 (2000).
Liu, D., et al.,J. Pharmacol Exp. Ther. 286:561 (1998).
Schwartz, M.W., et al.,Nature 404:661 (2000).
Xiao, S., et al.,Hypertension 37:645 (2001).
Zacharia, L.C.,Hypertension 37:658 (2001).
Zhang, Y., et al.,Nature 372:425 (1994).
Dubey R.K., et al., Abstract,Hypertension, National Library of Medicine, No. 9453356, Jan. 1998.
Nadal, Angel, et al.,The FASEB Journal 12:1341 (1998).
Dubey Raghvendra K.
Jackson Edwin K.
Tofovic Stevan P.
Badio Barbara P.
The McCallum Law Firm LLC
University of Pittsburg
LandOfFree
Administration of estradiol metabolites for the treatment or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of estradiol metabolites for the treatment or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of estradiol metabolites for the treatment or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3689349